资本风云|减肥药拉动药明康德狂赚120亿,实控人李革等人忙套现60亿

子弹财经
Nov 09

减肥药风潮席卷全球,以礼来的替尔泊肽和诺和诺德的司美格鲁肽为代表,GLP-1减肥药正在重塑医药产业的商业格局。除两大巨头之外,国内外药企纷纷入局,从适应症扩展、渠道布局、品牌竞争到价格战,下游市场打得不可开交。而上游提供合成原料与生产工艺的“卖水人”,却在这场浪潮中悄然成为大赢家。药明康德正处在这条产业链的核心节点。作为全球最大的CRDMO(医药合同研究、开发与生产)公司之一,药明康德不直接生产...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10